Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.



More Latest News

The Annual Report and Long-Range Plan Released for Fiscal Year 2020-21
November 1, 2021

The Annual Report and Long-Range Plan for Fiscal Year 2020-21
is now online. Continue reading


Fourth Quarter Performance Report
October 14, 2021

Released for the
2020-21 Fiscal Year Continue reading